169 related articles for article (PubMed ID: 20383850)
21. Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
Ishida A; Kanoh K; Nishisaka T; Miyazu Y; Iwamoto Y; Kohno N; Miyazawa T
Intern Med; 2004 Aug; 43(8):718-20. PubMed ID: 15468973
[TBL] [Abstract][Full Text] [Related]
22. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
23. Photodynamic therapy for choroidal metastasis from carcinoid tumor.
Harbour JW
Am J Ophthalmol; 2004 Jun; 137(6):1143-5. PubMed ID: 15183811
[TBL] [Abstract][Full Text] [Related]
24. [A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Tanaka H; Okamoto T; Shinyama M; Matsumura S; Fujii T
Gan To Kagaku Ryoho; 2013 Aug; 40(8):1067-9. PubMed ID: 23986053
[TBL] [Abstract][Full Text] [Related]
25. Photodynamic Therapy for Choroidal Metastasis.
Ghodasra DH; Demirci H
Am J Ophthalmol; 2016 Jan; 161():104-9.e1-2. PubMed ID: 26432928
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
Lai SW; Ho CL; Dai MS; Chen WL; Chang PY; Wu YY; Perng CL; Lai CY
J BUON; 2014; 19(2):459-65. PubMed ID: 24965407
[TBL] [Abstract][Full Text] [Related]
27. [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
Kato T; Nakashima M; Yoshimura K; Imao M; Goto H; Yasuda S; Sano K
Nihon Kokyuki Gakkai Zasshi; 2005 Nov; 43(11):700-3. PubMed ID: 16366371
[TBL] [Abstract][Full Text] [Related]
28. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
29. Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
Bashir ES; Kwan AK; Chan CY; Mun Keong K
J Orthop Surg (Hong Kong); 2016 Dec; 24(3):421-423. PubMed ID: 28031519
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Changes in Bilateral Choroidal Metastasis from Non-Small Cell Lung Cancer with Response to Afatinib: A Case Report.
Zhou HP; Tanaka R; Tsuji H
Ocul Immunol Inflamm; 2020 Aug; 28(6):860-863. PubMed ID: 31013174
[TBL] [Abstract][Full Text] [Related]
31. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
32. Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Wang H; Zhang G; Li P; Yan X; Wang Q; Zhu H; Qi G; Fan Q; Ma Z
Pharmazie; 2012 Jan; 67(1):80-5. PubMed ID: 22393836
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Liam CK; Ruthranesan M; Lee CH; Pang YK; Chua KT; Lim BK
Asia Pac J Clin Oncol; 2012 Sep; 8(3):267-74. PubMed ID: 22897510
[TBL] [Abstract][Full Text] [Related]
34. Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Asami K; Kawahara M; Atagi S; Kawaguchi T; Okishio K
Lung Cancer; 2011 Aug; 73(2):211-6. PubMed ID: 21272953
[TBL] [Abstract][Full Text] [Related]
35. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Kozlov V; Karpov I; Kovalenko S; Shamanin V
Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
[TBL] [Abstract][Full Text] [Related]
36. [A case of advanced adenocarcinoma of the lung which maintained complete response for 5 years by treatment with gefitinib].
Matsuzaki T; Terashima T; Ogawa R; Naitou A; Miyauchi J; Morishita T
Nihon Kokyuki Gakkai Zasshi; 2010 Aug; 48(8):600-3. PubMed ID: 20803978
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Liam CK; Pang YK; Leow CH
Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
[TBL] [Abstract][Full Text] [Related]
38. Subacute visual loss from choroidal metastasis.
Degenring RF; Kamppeter B; Jaeger M; Libera T; Sauder G; Jonas JB
Acta Ophthalmol Scand; 2004 Jun; 82(3 Pt 1):304-5. PubMed ID: 15115452
[No Abstract] [Full Text] [Related]
39. Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
Funakoshi Y; Takeuchi Y; Maeda H
Asian Cardiovasc Thorac Ann; 2013 Aug; 21(4):482-4. PubMed ID: 24570539
[TBL] [Abstract][Full Text] [Related]
40. Optical coherence tomography for evaluation of photodynamic therapy in symptomatic circumscribed choroidal hemangioma.
Liu W; Zhang Y; Xu G; Qian J; Jiang C; Li L
Retina; 2011 Feb; 31(2):336-43. PubMed ID: 21102373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
